First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?
2018 ◽
Vol 81
(3)
◽
pp. 443-453
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):